We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.88% | 5.75 | 5.50 | 6.00 | 5.85 | 5.75 | 5.85 | 916,939 | 08:00:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Miscellaneous Metal Ores,nec | 17.31M | -6.1M | -0.0102 | -5.64 | 34.51M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/9/2021 13:13 | The share price could well drop as usual | b00mb0y | |
14/9/2021 12:55 | and the share price not reacting? | ali47fish | |
14/9/2021 12:35 | Extraordinary that they didn't at least RNS NON it. | 18bt | |
14/9/2021 11:29 | Thanks 33Mick . Excellent news ! | ywdis | |
14/9/2021 10:56 | The "Queens Award" is actually very difficult to achieve. They go over every part of the company meticulously especially the books to check it's impeccably run. It usually results in a decent uptick in business but honestly can't see how it helps a company as niche as KMK. I'm actually surprised KMK got it to be honest considering the losses they have delivered to shareholders over the years! | ark87 | |
14/9/2021 10:23 | I've just emailed CBRNE world magazine who are based in Winchester to ask if they were visiting the London Exhibition this week and if they would be reporting on Kromek's 'world first Patho detection system'...can't hurt.. Falcon Communications UK Suite 31, Basepoint 1 Winnall Valley Road Winchester SO23 0LD United Kingdom | 33mick | |
14/9/2021 09:52 | New out day posted by Prometheus on LSE - Watch "Kromek's Queens Award Presentation" on YouTube | 33mick | |
14/9/2021 09:10 | Why isn’t all that on the news? | b00mb0y | |
14/9/2021 09:08 | Thanks 33mick. Really useful. | dogwalker | |
14/9/2021 08:59 | Today's update on Kromek's events page Latest Kromek is exhibiting at DSEI 2021 14/09/2021 "A world first: Kromek to exhibit a new Covid-19 detector; handheld devices at DSEI, London ExCel Centre, 14-17 September 2021 Kromek, the biological and radiation detection specialists based in Sedgefield, County Durham, will exhibit their new, standalone Covid-19 detector at DSEI, at London’s ExCel Centre from 14-17 September 2021. The company will be part of the MakeUK stand (Hall 2, Stand 429). The standalone, fully autonomous Covid-19 Detection System uses a targeted assay to sample the air every 30 minutes to confirm whether the disease – in all its potential variants – is present. Eighteen months into the worldwide Covid-19 pandemic, this high-speed, highly accurate device offers a revolutionary capability to understand and control the spread of the disease. The Covid-19 detection system can be used indoors or outdoors, in static or mobile capacities and can be run continuously or as required. The device will report either the presence or absence of Covid-19. The speed and accuracy of reporting and localised monitoring enables a detailed understanding of the spread of the virus, and allows mitigating actions to be taken such as targeted testing or decontamination." "Dr Arnab Basu, Kromek’s Chief Executive Officer, said “I am delighted that our unique Covid-19 detector is making its debut at DSEI. It is a device that we designed to help the world get back to as normal a situation as possible despite the ongoing global pandemic.” Kromek will also be featuring its latest hand-held radioisotope detection device, the D5 RIID, the smallest, lightest and most accurate wearable detector currently available. The D5 RIID has been designed to detect the latest radiological hazards and to defeat the CBRN threat. It has an extensive built-in radioisotope library, to accurately identify even the smallest samples and the lowest dose rates. The D5 RIID can fit into the palm of one hand and is intuitive to operate, even while wearing full PPE. Weighing just 660g, it has a >24-hour endurance and has a networked capability to allow results to be transmitted to wherever they are needed in real time. Craig Duff, Kromek’s CBRN Business Manager, said “We are looking forward to demonstrating our range of handheld radiation detectors to the military CBRN community at DSEI this week.” | 33mick | |
14/9/2021 07:47 | What really doesn’t matter is the “likes / dislike” on each written blog. Rampers v trolls. | b00mb0y | |
13/9/2021 20:11 | I wonder how much if any these boards effect the share price? I’ve always assumed the effect to be minimal with a pretty tiny readership... there must be about 10 people who make a comment at least once a month. Wonder how many read what’s written outside of those 10people | aqc888 | |
13/9/2021 11:50 | Boomboy, guidance was commercialisation by the end of the year. (Of the covid detector) or by the end of the financial year for the wide spectrum biological pathogen detector. I was hoping there would be positive news at the AGM and upon that the share price would reach 25p. However there wasn’t any new news. | aqc888 | |
13/9/2021 10:32 | Can anybody please explain in simple terms the underlying scientific methods which Kromek are using for pathogen/covid detection? Thank you. ALL IMO. DYOR. QP | quepassa | |
13/9/2021 09:23 | Sad state of affairs is this kmk. I was hoping AQC was going to be correct with his .25p target for Friday gone. Then some more considering Wednesday’s detectors showcase. Don’t look like it’s going to hit .25p ever. | b00mb0y | |
13/9/2021 08:01 | Correction: Boris to talk tomorrow now, on living/managing with Covid going forward. | davethechef | |
12/9/2021 16:35 | I'm thinking that there's a massive difference between sequencing bacterial strains (eg. anthrax - who cares)) and Covid type viruses. Although whole RNA strands can now be sequenced using nanopore methods, such viruses seem to have a poorly understood error checking replication process, possibly involving the NSP14 protein amoungst others. Specificity is thus paramount. The Polio virus and its vaccine only now differ in one nucleotide, I believe, by way of an example. A specificity at this level would be awesome. IMO - GLA | simithy | |
12/9/2021 16:34 | ...because they've realised they've wasted more public money on pie in the sky gadgetry. Taken hook line and sinker like a lot in the early panic days i suspect. | vickiitwo2 | |
11/9/2021 21:46 | Why are politicians shying away from mentioning the investment they’ve made in a U.K. company that is so relevant to the biggest news story of the last 1.5yrs? I just don’t get it. Absolutely zero mention of the detector by any politician apart from the mayor of Teesside. Usually politicians are desperate to show various ways they are attempting to tackle problems, take credit for ground breaking British innovations. Yet here it’s complete and utter silence. | aqc888 | |
11/9/2021 21:28 | What strikes me as a bit weird is no public mention of the detector by a government minister despite the government giving Kromek £1.25m, then another £350k to develop the covid detector. Even when Kwasi Kwarteng, Secretary of State for Business Energy and Industrial Strategy (BEIS) visited Kromeks office a month ago he didn’t even make a passing comment about the detector to the press in any of his interviews. Very odd given Kromek have been given government backing and Kromeks biological pathogen detector is so relevant to the news. | aqc888 | |
11/9/2021 18:50 | To be fair it wasn’t anything new from the annual report, see below... Biological-Threat Detection The outbreak of COVID-19 has exposed the world to the severity of biological threats and their potential impact on public health and the global economy, demonstrating the need to rapidly evolve bio-security systems and associated technologies. Kromek had already commenced development work on a biological-threat detection solution prior to the outbreak of the pandemic and significantly progressed its activities in this market during the year. This development has continued post period. Since H2 2019, Kromek has been working with the Defense Advanced Research Projects Agency (“DARPA” Over the past two years, milestones achieved under this DARPA programme have included the development of a vehicle-mounted biological-threat identifier that can be deployed as a mobile wide-area bio-surveillance system. Post period, the Group received a $6m contract from DAPRA for the next phase of the programme that will seek to deliver a completely automated wide spectrum airborne pathogen detection system that is fully mobile and runs autonomously. This system is being designed to be networkable and provide wide-area monitoring capability in near real time. With the onset of the pandemic, Kromek also focused on the development of its technology for applications specifically related to COVID-19 detection. This included working under a programme funded by Innovate UK to customise the Group’s biological threat-detection solution to support end-use cases for COVID-19 detection and mitigation, and to then undergo piloting with those user groups. The Group engaged with potential customers for the system to develop deployment models and identify how it can best fit their needs ahead of customisation. In the second half of the year, the Group commenced piloting the system for the detection of airborne COVID-19 at an airport. Post period, the piloting has been expanded to include schools, a second airport, being Teesside International Airport, and other locations. The Group has also engaged in validation of the technology in third party laboratories and the results are very positive on both the detection levels, sensitivity and false alarm rates, making the technology performance comparable to existing RT PCR test protocols. | aqc888 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions